Traditional Chinese medicine granule for treating postmenopausal osteoporosis and preparation method thereof
Through traditional Chinese medicine granules composed of Ligustrum, Morinica, Bone Saccharomycea and Alisma, the problem of yin and yang balance and kidney deficiency retention in the treatment of postmenopausal osteoporosis is solved, and by promoting osteoblast activity and inhibiting osteoclasts , significantly improve bone loss and microstructure, delay the disease progression, and achieve more effective therapeutic effects.
Patent Information
- Application Number
- CN202411111154.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-12
- Publication Date
- 2024-11-22
AI Technical Summary
The treatment of postmenopausal osteoporosis is mainly focused on inhibiting bone resorption or promoting bone formation, but ignores the problem of disease retention caused by yin and yang balance and kidney deficiency, resulting in limited treatment effect.
The traditional Chinese medicine granules composed of Ligustrum, Morinica, Bone Scabbage and Alisma are prepared by reflux extraction of ethanol solution, concentrated under reduced pressure, mixed with dextrin, and dried to make granules, achieving double supplementation of yin and yang, and supplementation without The effects of stagnation and elimination of evil and strengthening the body.
This traditional Chinese medicine granules regulates the OPG/RANKL ratio by promoting the expression of alkaline phosphatase in osteoblasts, increasing calcified nodules, and increasing the expression of osteoblast-related cytokines, inhibits osteoclast-related factors, and improves bone mass loss and bone microscopy Structural disorders delay the progression of osteoporosis and significantly improve the treatment effect.
Smart Images

Figure CN118986899A_ABST
Abstract
Description
[0001] This application is a divisional application. The application number of the original application is: 202310850911.2, the application date is 2023.07.12, and the name of the invention is: A traditional Chinese medicine for treating postmenopausal osteoporosis and its preparation method. Technical Field
[0002] The invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine granule for treating postmenopausal osteoporosis and a preparation method thereof. Background Art
[0003] Postmenopausal osteoporosis (PMOP) is a metabolic bone disease caused by the decline of ovarian hormone synthesis in postmenopausal women. It is characterized by systemic bone loss and changes in bone microstructure, resulting in increased bone brittleness and high susceptibility to fractures. Osteoporosis has become a serious public health problem, and its incidence has remained high. Osteoporosis fractures are the most common complication, and are prone to fractures of the forearm, wrist, cone and hip, among which hip fractures are the most serious. Patients with hip fractures are unable to move, and 12% to 40% may die from various complications within 1 year, which seriously affects the quality of life of patients. The huge medical expenses and nursing costs increase the economic burden on patients. In the early stage of menopause, the use of anti-resorptive drugs alone can achieve the purpose of bone protection, but in the late stage of menopause, long-term treatment with osteosynthesis-promoting drugs is required to partially alleviate bone loss.
[0004] The treatment options recommended by the diagnosis and treatment guidelines for postmenopausal osteoporosis mainly include exercise therapy, physical therapy and drug therapy. Drug therapy mainly includes drugs that inhibit bone resorption, such as estrogen, calcitonin, and bisphosphonates, and drugs that promote bone formation, such as fluoride, growth hormone, and vitamin K. Studies on the treatment of postmenopausal osteoporosis with traditional Chinese medicine have been reported one after another. Based on clinical experience, effective treatment prescriptions and medicines have been summarized, which is an important way for traditional Chinese medicine to treat osteoporosis. In clinical practice, common treatment principles for postmenopausal osteoporosis include tonifying the liver and kidneys, strengthening the tendons and bones, and mainly tonifying the kidney yin and kidney yang. The kidney turbidity caused by deficiency leading to excess is often ignored.
[0005] Based on this, the present invention is proposed. Summary of the invention
[0006] The purpose of the present invention is to provide a Chinese medicine granule for treating postmenopausal osteoporosis and a preparation method thereof. The whole prescription can achieve the effects of replenishing both yin and yang, replenishing without stagnation, and eliminating evil and strengthening the body.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The invention provides a traditional Chinese medicine for treating postmenopausal osteoporosis. The medicine is prepared from the following components in parts by weight: 25-35 parts of Ligustrum lucidum fruit, 10-20 parts of Morinda officinalis root, 10-20 parts of Drynaria fortunei and 5-15 parts of Alisma orientalis.
[0009] The present invention also provides a method for preparing a traditional Chinese medicine for treating postmenopausal osteoporosis, comprising the following steps:
[0010] (1) Extract Ligustrum lucidum, Morinda officinalis, Drynaria fortunei, and Alisma orientalis by reflux extraction with ethanol solution;
[0011] (2) collecting the extract from step (1) and concentrating it under reduced pressure to obtain the Chinese medicine.
[0012] Preferably, in step (1), the mass ratio of the total mass of the Fructus Ligustri Lucidi, Morinda Officinalis, Rhizoma Drynariae and Rhizoma Alismatis to the ethanol solution is 1:9-11; and the volume fraction of the ethanol solution is 30-70%.
[0013] Preferably, the reflux extraction in step (1) is performed 1 to 3 times; the time for each extraction is 0.5 to 1.5 hours, and the temperature for each extraction is 70 to 90 degrees Celsius.
[0014] Preferably, the pressure of the reduced pressure concentration in step (2) is 0.1-0.2 MPa; and the temperature of the reduced pressure concentration is 60-70°C.
[0015] Preferably, the relative density of the extract concentrated in step (2) is 1.25-1.30 g / mL.
[0016] Preferably, the Chinese medicine is mixed with auxiliary materials to form a soft material, which is sieved and granulated, and dried under reduced pressure to prepare Chinese medicine granules.
[0017] Preferably, the auxiliary material is dextrin; the mass ratio of the traditional Chinese medicine to dextrin is 1:0.8-1.1.
[0018] Preferably, the mesh size of the sieving is 10 to 14 meshes.
[0019] Preferably, the specific operation of the reduced pressure drying is: drying at 0.1-0.2 MPa and 45-55° C. for 35-37 hours.
[0020] Postmenopausal osteoporosis is based on kidney deficiency, and kidney turbidity is retained. Due to deficiency, the disease is retained. The treatment considers both yin and yang to be supplemented, and both tonification and purgation are taken into account. The present invention proposes a treatment principle of tonifying the kidney and purging turbidity. The invented Zhenrong Decoction is composed of Ligustrum lucidum, Morinda officinalis, Drynaria fortunei, and Rhizoma alismatis. "Shen Nong's Herbal Classic" records that Ligustrum lucidum can enter the foot Shaoyin kidney meridian, and is also an important medicine for removing heat and benefiting essence. "Ben Cao Bian Du" believes that Ligustrum lucidum "has the function of sweet, cool, pure and quiet, and enters the kidney to benefit yin." Morinda officinalis is slightly warm and not dry, can nourish the original yang, enter the foot Shaoyin kidney meridian, and is an important medicine for kidney deficiency. "Ben Cao Tong Xuan" calls Morinda officinalis "the blood medicine of the kidney meridian", which can strengthen the bones and muscles, cure impotence, benefit the essence and qi, and stop nocturnal emission. "Compendium of Materia Medica" records that "it is suitable for entering the foot Shaoyin kidney meridian and treating inter-bone diseases", and "Medicine Cage Xiaopin" says that it "bitter and hardens the kidney, warms and promotes blood circulation, replenishes injuries and fractures, and treats bone atrophy." Alisma orientalis belongs to the kidney meridian, and can dispel dampness, promote diuresis, and purge turbidity. "Compendium of Materia Medica Reading" records that "Alismatis orientalis is sweet, light, salty, and cold, and enters the kidney and bladder to guide the lower part of the body to dampness, dirt, and turbidity." Natural dampness and heat are removed, the fire of the phase is lowered, and the evil is removed, so it is often used in kidney-tonifying medicine. "In the present invention, Ligustrum lucidum is the main medicine, which is mild in nature and is good at nourishing the liver and kidney, replenishing yin and producing essence; Morinda officinalis and Drynaria fortunei are both ministerial medicines, and Alisma orientalis is the adjuvant medicine. The whole prescription can achieve the effects of tonifying both yin and yang, tonifying without stagnation, and dispelling evil and strengthening the body. From the perspective of tonifying the kidney and purging turbidity, the present invention considers tonifying kidney yin and kidney yang, tonifying without stagnation, and guiding evil qi to go away, thereby restoring the body's internal balance.
[0021] Animal and cell experiments further verified that the Chinese medicine prepared by the present invention has a good therapeutic effect on the prevention and treatment of postmenopausal osteoporosis. The Chinese medicine prepared by the present invention can promote the expression of alkaline phosphatase in osteoblasts, increase calcified nodules, increase the gene expression and protein expression levels of osteoblast-related cytokines RUNX2, ALP, and Osterix, and can increase the OPG / RANKL ratio at both molecular and protein levels. After administration, it was found that osteoclast-related transcription factors decreased, inhibited the activation of NFATc1 and c-Fos induced by RANKL, and the phosphorylation level of PI3K / Akt decreased after the intervention of the formula. Formula treatment can improve bone loss and bone microstructure disorder in OVX rats, thereby delaying the disease progression of postmenopausal osteoporosis. Further mechanism studies have found that the formula may upregulate OPG protein expression, increase the OPG / RANKL ratio, play a role in bone protection, downregulate the expression of bone resorption-related factors downstream of the RANKL / RANK signaling pathway, participate in regulating bone metabolism balance, and achieve the therapeutic effect of PMOP. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0023] Figure 1 This is the cell growth state during the culture and identification of primary osteoblasts in Experimental Example 1;
[0024] Figure 2 This is the effect of different concentrations of Zhenrong Decoction on osteoblast activity at different time points in Experimental Example 1.
[0025] Figure 3 After osteoblasts were treated with different concentrations of Zhenrong Decoction-containing serum in Experimental Example 1 for 21 days, the formation of calcium nodules was observed by Alizarin Red staining (A), and the calcium nodules were dissolved and semi-quantitated (B). *P<0.05.
[0026] Figure 4 The expression levels of Runx2, ALP, Osterix, and OPG / RANKL mRNA in skull-derived osteoblasts after intervention with different concentrations of drug-containing serum in Experimental Example 1 for 72 hours, compared with the control group, **p<0.01;
[0027] Figure 5 The expression levels of ALP, Osterix, Runx2, and OPG / RANKL proteins in skull-derived osteoblasts were detected after 72 hours of intervention with different concentrations of drug-containing serum in Experimental Example 1 (A) and semi-quantitative analysis (B). Compared with the control group, *p<0.05, **p<0.01;
[0028] Figure 6 The results of inducing RAW264.7 cells with 50 ng / mL RANKL and using TRAP staining in Experimental Example 1 are 100X;
[0029] Figure 7 Effects of different concentrations of Zhenrong decoction at different time points (24h, 48h, 72h, 96h) on RANKL-induced RAW264.7 cell viability in Experimental Example 1. Compared with the control group, *p<0.05, **p<0.01;
[0030] Figure 8The changes in the expression levels of c-fos, NFATc1, CTSK, Trap, Integrinαvβ3 and MMP-9 mRNA in RAW264.7 cells after 72 hours of intervention with different concentrations of Zhenrong Decoction-containing serum under the induction of RANKL 50 ng / mL in Experimental Example 1, compared with the control group, ***p < 0.001);
[0031] Fig. 9 The expression levels of TRAF6, c-fos, NFATc1, and MMP-9 proteins were detected after 72 hours of intervention with serum containing Zhenrong Decoction in Experimental Example 1;
[0032] Fig.10 The expression level of PI3K / AKT protein was detected after 72 hours of intervention with serum containing Zhenrong Decoction in Experimental Example 1;
[0033] Fig.11 This is the Masson staining result of the tibia sample of rats with osteoporosis treated with Zhenrong Decoction for 12 weeks in Experimental Example 1 (100X);
[0034] Fig.12 In Experimental Example 1, microCT scanning was used to observe the microstructure of the tibial metaphysis bone after the bone tissue of the tibial metaphysis was fixed;
[0035] Fig.13 The microscopic parameters BMD (B), BV / TV (C), Tb.N (D), Tb.Th (E) were obtained by microCT scanning analysis after fixation of the tibial metaphysis bone tissue in Experimental Example 1 (Note: a: compared with OVX, *P < 0.05, **P < 0.01, **P < 0.001; b: compared with the SHAM group, ##P < 0.01.);
[0036] Fig.14 The results of the maximum load measurement of the tibia of ovariectomized rats in Experimental Example 1 (Note: a: compared with OVX, *P < 0.05; b: compared with the SHAM group, #P < 0.05);
[0037] Fig.15 The effect of Zhenrong Decoction on blood biochemical indexes of ovariectomized rats in Experimental Example 1 (Note: a: compared with OVX, *P<0.05, **P<0.01; b: compared with SHAM group, ##P<0.01);
[0038] Fig.16 This is the effect of Zhenrong Decoction on osteoblast formation-related indicators in ovariectomized rats in Experimental Example 1 (Note: a: compared with OVX, *P < 0.05, **P < 0.01, ***P < 0.001; b: compared with SHAM group, ##P < 0.01);
[0039] Fig.17 This is the effect of Zhenrong Decoction on the protein levels of bone formation-related factors in femur of ovariectomized rats in Experimental Example 1 (Note: a: compared with OVX, *P<0.05, **P<0.01; b: compared with SHAM group, #P<0.05, ##P<0.01);
[0040] Fig.18 The changes in the mRNA levels of osteoclast formation and differentiation-related factors of Zhenrong Decoction in ovariectomized rats in Experimental Example 1 (Note: a: compared with OVX, *P < 0.05, **P < 0.01; b: compared with SHAM group, ##P < 0.01);
[0041] Fig.19 This is the change of protein levels of osteoclast resorption-related factors in ovariectomized rats detected by Zhenrong Decoction in Experimental Example 1 (Note: a: compared with OVX, *P<0.05, **P<0.01; b: compared with SHAM group, ##P<0.01). DETAILED DESCRIPTION
[0042] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0043] Example 1
[0044] A method for preparing Zhenrong Granules, a traditional Chinese medicine granule for treating postmenopausal osteoporosis, comprises the following steps:
[0045] 25g of Ligustrum lucidum, 10g of Morinda officinalis, 10g of Drynaria fortunei and 5g of Alisma orientalis were placed in a round-bottom flask, and 30% ethanol solution by volume was added at a mass ratio of 1:9, and refluxed for extraction at **℃ for 0.5h. The extract was concentrated at 0.1MPa and 60℃ to a relative density of 1.25g / mL to obtain Chinese medicine. The Chinese medicine was mixed with dextrin at a mass ratio of 1:0.8 to prepare a soft material, and granules were sieved with a 10-mesh sieve. The granules were dried at 0.1MPa and 45℃ for 35h, and passed through a 9-mesh sieve to obtain the Chinese medicine granules - Zhenrong granules.
[0046] Example 2
[0047] A method for preparing Zhenrong Granules, a traditional Chinese medicine granule for treating postmenopausal osteoporosis, comprises the following steps:
[0048] 35g of Ligustrum lucidum, 20g of Morinda officinalis, 20g of Drynaria fortunei and 15g of Alisma orientalis were placed in a round-bottom flask, and 70% ethanol solution by volume was added in a mass ratio of 1:11, and refluxed for extraction for 3 times at **℃, each time for 1.5h. After the extraction, the extract was concentrated at 0.2MPa and 70℃ to a relative density of 1.30g / mL to obtain the traditional Chinese medicine, and the traditional Chinese medicine was mixed with dextrin in a mass ratio of 1:1.1 to prepare a soft material, and granulated with a 14-mesh sieve, dried at 0.2MPa and 55℃ for 37h, and passed through a 12-mesh sieve to obtain the traditional Chinese medicine granules - Zhenrong granules.
[0049] Example 3
[0050] A method for preparing Zhenrong Granules, a traditional Chinese medicine granule for treating postmenopausal osteoporosis, comprises the following steps:
[0051] 30g of Ligustrum lucidum, 15g of Morinda officinalis, 15g of Drynaria fortunei and 10g of Alisma orientalis were placed in a round-bottom flask, and 50% ethanol solution by volume was added in a mass ratio of 1:10, and refluxed for extraction twice at **℃, each time for 1h. After the extraction, the extract was concentrated at 0.1MPa and 65℃ to a relative density of 1.28g / mL to obtain the traditional Chinese medicine, and the traditional Chinese medicine was mixed with dextrin in a mass ratio of 1:1 to prepare a soft material, and granulated with a 12-mesh sieve, dried at 0.1MPa and 50℃ for 36h, and passed through a 10-mesh sieve to obtain the traditional Chinese medicine granules - Zhenrong granules.
[0052] Experimental Example 1
[0053] 1. Preparation of drug-containing serum
[0054] Take 200 g of the Chinese medicine granules obtained in Example 3, add 1.5 L of 50% ethanol by volume and reflux extract twice (the extraction time is 1 h), combine the filtrates obtained twice and concentrate to obtain an intragastric solution with a relative density of 0.9 g / mL - Zhenrong Decoction (converted to a rat intragastric dose of 2.2 g / (kg·d) per day according to the clinical dose).
[0055] Ten 6-week-old male SD rats were gavaged with Zhenrong Decoction at a dose of 2.2 g / kg for 7 consecutive days, and samples were collected 15 minutes after the last dose on the 7th day. After anesthesia with isoflurane anesthesia machine, blood was collected from the abdominal aorta and placed in a blood collection tube without additives. The blood volume was 5 mL, and the blood was centrifuged at room temperature for 1 hour (4°C 3000 rpm, 10 minutes). The upper drug-containing serum was transferred into a cryopreservation tube and placed in a -80°C ultra-low temperature refrigerator for standby use. Another 10 rats were gavaged with blank saline according to the above Zhenrong Decoction dosing regimen, and the blank serum was separated and stored at -80°C for standby use.
[0056] Serum sample preparation: 2 mL of -80°C frozen drug-containing serum was accurately pipetted into a centrifuge tube, 10 mL of methanol was added, vortexed for 2 min, centrifuged at 10,000 r / min for 10 min, the supernatant was removed, and dried with N2 at room temperature. The residue was re-dissolved with 500 μL of 50% ethanol by volume by ultrasonication (500w ultrasonication for 5 min), placed in a high-speed centrifuge at 10,000 r / min, centrifuged for 10 min, and the supernatant was removed, which was the Zhenrong Decoction drug-containing serum test sample. The blank serum was treated in the same way to prepare the blank serum test sample.
[0057] 5% drug-containing serum: Take 50 μL of drug-containing serum test sample and add 250 μL of methanol for alcohol precipitation, centrifuge to obtain the supernatant, blow dry with nitrogen gas, and reconstitute with 1 mL of α-MEM medium or 1 mL of DMEM medium respectively;
[0058] 10% drug-containing serum: Take 100 μL of drug-containing serum test sample and add 250 μL of methanol for alcohol precipitation. Centrifuge to obtain the supernatant, blow dry with nitrogen gas, and reconstitute with 1 mL of α-MEM medium or 1 mL of DMEM medium respectively;
[0059] 20% drug-containing serum: Take 200 μL of drug-containing serum test sample and add 250 μL of methanol for alcohol precipitation. Centrifuge to obtain the supernatant, blow dry with nitrogen gas, and reconstitute with 1 mL of α-MEM medium or 1 mL of DMEM medium.
[0060] The drug-containing serum reconstituted with 1 mL of α-MEM medium was used for primary osteoblasts, and the drug-containing serum reconstituted with 1 mL of DMEM medium was used for RAW264.7 cells.
[0061] 2. Primary osteoblast assay
[0062] 2.1. Primary osteoblast culture and identification
[0063] SD mice born 72 hours ago were selected to extract osteoblasts from the skull. After being killed by rapid neck dislocation, the mice were disinfected with 75% ethanol, moved into a biosafety cabinet, the neck was cut, the skull was separated, and the skull was soaked in 7.4M PBS. The scissors and forceps were burned on an alcohol lamp. After cooling for 30 seconds, the skull surface tissue was cleaned; the skull was transferred to a new culture dish containing PBS, the skull was cut as much as possible, the PBS was discarded, 6mL of pancreatic enzyme with a volume fraction of 0.25% was added, and the skull was digested in a 37℃ incubator for 10 minutes. After blowing and mixing with a pipette, the pancreatic enzyme was discarded, and 6mL of 0.2% type I collagenase was added. The mice were placed in a 37℃ incubator for digestion for 60 minutes. The mixture was mixed every 10 minutes. After 60 minutes, the collagenase solution was collected in a centrifuge tube and centrifuged at 12000rpm for 3 minutes. After centrifugation, the precipitate can be seen. Discard the supernatant, resuspend in α-MEM (purchased from Gibco, catalog number 41061037, with 10% FBS + 1% penicillin-streptomycin), and culture in a 37°C incubator for 12 hours. Figure 1 As shown in A, cells can be seen attached to the wall in the shape of spindles, cones and polygons. After culturing for 12 hours, a few attached cells can be seen, and then the medium is changed. After washing with PBS, α-MEM is added and culture is continued at 37°C until the third day. Figure 1 As shown in B, the number of cells increased and gradually became confluent; on the fifth day of culture, Figure 1 As shown in C, the cells gradually form a "paving stone" growth trend, and the cell confluence rate reaches more than 90%, and the cells can be subcultured; when it reaches the third generation, Figure 1 As shown in D, cells in this state are taken for alizarin red staining. Figure 1 As shown in E, nodules can be seen in cells stained with Alizarin Red. When the cells were cultured for 10 days, they were stained again. Figure 1 As shown in middle F, the cells showed obvious calcified nodules.
[0064] 2.2. CCK8 determination of drug-containing serum intervention concentration in each group
[0065] The effect of Zhenrong Decoction on the activity of skull-derived osteoblasts was detected by CCK8 kit. The skull-derived osteoblasts (adherent cells at the third passage) cultured in 2.1 were cultured in culture flasks (Corning T25cm 2 ) were added with 5 ml of blank serum test sample (0%), 5%, 10%, and 20% drug-containing serum prepared in part 1, respectively, and cultured in differentiation induction medium (purchased from Haixing Biology) at 37°C and 5% CO2 for 96 h. Figure 2 As shown, it was found that 5% and 10% had no obvious toxicity to cells at different time points (24h, 48h, 72h, 96h). Under this premise, 5% and 10% were selected for subsequent osteoblast stimulation induction experiments.
[0066] 2.3. Detection of alkaline phosphatase in osteoblast culture supernatant by ALP method
[0067] Primary osteoblasts were inoculated in a 24-well plate, and when the cell confluence reached 80%, serum-free medium was added to starve for 12 hours, the medium was discarded, and physiological saline blank serum, 5%, and 10% drug-containing serum (prepared in Part 1) were added respectively, and culture was continued for 72 hours. The cell supernatant culture fluid was collected, 1300r / min, centrifuged for 10 minutes, and the supernatant was taken to determine the content of alkaline phosphatase. (According to the ALP kit (A059-2, purchased from Nanjing Jiancheng Bioengineering Institute), the corresponding reagents were configured, and then the ALP content was calculated by the formula ALP (King's unit / 100mL) = (measured sample OD / standard OD) × the amount of phenol in the standard × (100mL / 0.05mL) (repeated 5 wells)). The results are shown in Table 1. After 72 hours of culture, the alkaline phosphatase content of 5% Zhenrong Decoction drug-containing serum began to be higher than that of the physiological saline blank serum group, and the ALP content of 10% Zhenrong Decoction drug-containing serum was more significant (P<0.05). This indicates that the Zhenrong Decoction of the present invention can promote the expression of alkaline phosphatase in osteoblasts.
[0068] Table 1 Effect of Zhenrong Decoction on ALP activity of osteoblasts (n=6, )
[0069] Group ALP content (mg / mL) Saline blank serum 0.027±0.0093 Zhenrong Decoction Medicated Serum (5%) 0.1213±0.02* Zhenrong Decoction Medicated Serum (10%) 0.1507±0.06*
[0070] 2.4. Zhenrong Decoction-containing serum promotes the maturation and differentiation of osteoblasts
[0071] Figure 1 Mineral deposition (calcium nodules) appeared in the late stage of osteogenic differentiation. To detect the formation of calcium nodules, after the osteogenic induction in Section 2.2, the cells in the blank serum group (control), 5% (ZRD-5), 10% (ZRD-10), and drug-containing serum groups were cultured for 21 days. The medium was changed every 3 days during the culture period, for a total of seven times. After the culture was completed, alizarin red staining was performed and semi-quantitative analysis was performed. The results are shown in Figure 3 As shown in the figure, Zhenrong Decoction-containing serum promotes the formation of osteoblast calcium nodules. The 5% Zhenrong Decoction-containing serum is higher than the saline blank serum group, and the 10% Zhenrong Decoction-containing serum calcified nodules are more significant (P<0.05). This is consistent with the results of the ALP method test in Section 2.3 (the increase in alkaline phosphatase and the generation of calcified nodules both indicate that the drug has the ability to promote osteogenesis), and Zhenrong Decoction can also increase calcified nodules.
[0072] 2.5. qPCR detection of bone formation-related factors RUNX2, Osterix, ALP, OPG / RANKL mRNA expression results
[0073] According to the results of 2.2, after 5% and 10% drug-containing serum intervened osteoblasts for 72 h, qPCR was used to detect the mRNA expressions of bone formation-related factors RUNX2, Osterix, ALP, and OPG / RANKL in the control, ZRD-5, and ZRD-10 groups. The results are as follows Figure 4 As shown, compared with the normal saline blank serum (control), the expression levels of RUNX2, Osterix, ALP, and OPG / RANKL mRNA related to osteoblast formation in the ZRD-5 and ZRD-10 groups were increased. It is speculated that the Zhenrong Decoction-containing serum exerts its effect on the proliferation of osteoblasts by regulating the above factors.
[0074] 2.6. Western Blot detection of bone formation-related factors RUNX2, Osterix, ALP, OPG, and RANKL protein expression results
[0075] (1) According to the results of 2.2, osteoblasts were seeded in 6-well plates (1×10 5 ), cultured cells with 0, 5% and 10% drug-containing serum, 2 ml per well. After 72 hours of intervention, the α-MEM medium (containing 10% FBS + 1% PS) was discarded, 300 μL RIPA lysis buffer + 10 μL PMSF was added to each well of cells, cells were lysed on ice, centrifuged at 14000 rpm, 4°C for 30 min, protein was extracted, and subsequent experiments were performed after measuring the protein concentration.
[0076] (2) Preparation and loading of SDS-PAGE gel: Prepare the separation gel and concentrated gel of the required concentrations in a fume hood, add the separation gel slowly between clean glass plates with a thickness of 1.0, flatten the separation gel interface with anhydrous ethanol, discard the anhydrous ethanol after the separation gel is completely solidified, dry it, slowly add 5% stacking gel, gently and quickly insert the sample comb into the upper layer of gel, keep it still, do not move it, and wait for the gel to solidify. Fix the gel plate on the electrophoresis clamp, add electrophoresis buffer, take out the sample comb vertically, observe the loading hole, add 3μL of protein pre-stained marker at one end, and load 20μg protein.
[0077] (3) Electrophoresis: Run electrophoresis at 75 V for 30 min to allow the samples to be neatly electrophoresed into the stacking gel. Run electrophoresis at 140 V for 40 min and stop electrophoresis when the target protein is clearly separated.
[0078] (4) Transfer: When the electrophoresis is about to end, take out the transfer solution stored at 4°C and pour it into an enamel square tray. Remove the glass glue plate. Close to the side of the glass glue plate, carefully pry up the short glass plate with a spatula, cut the gel where the target protein is located, discard the rest, cut a 0.22um PVDF membrane slightly larger than the gel area, place it in methanol for activation for 30 seconds, and then place it in the transfer solution, keeping it moist throughout the process. Take a sandwich transfer clip, soak the filter paper in the transfer solution, and align and place it in the order of white plywood - sponge pad - filter paper - membrane - glue - filter paper - sponge pad - black plywood. Make sure there are no bubbles between the glue and the membrane. Use a roller to drive out the bubbles and close the transfer clip. Insert the transfer clip into the transfer tank in the positive and negative directions, add pre-cooled transfer solution, and put ice cubes outside the transfer tank to achieve rapid cooling to prevent excessive heat generation. Set the voltage to 100V and the time to 30min, which can be adjusted according to the molecular weight.
[0079] (5) Blocking: After the transfer is completed, take out the PVDF membrane, place it in a blocking solution incubation box, and block it on a shaker (speed 50 rpm) for 2 h.
[0080] (6) Primary and secondary antibody immunoreaction: After blocking, add the diluted primary antibody. Shake at 4°C (60 rpm) overnight. Recover the primary antibody the next day and wash the PVDF membrane with TBST on a shaker (90 rpm) 4 times for 5 min. Add the corresponding secondary antibody at a dilution of 1:10,000 according to the species of the primary antibody. Incubate at room temperature on a shaker (60 rpm) for 90 min. After removing the secondary antibody, wash with TBST on a shaker (90 rpm) for 10 min / time, 3 times.
[0081] Among them, the relevant information of the primary antibody and the secondary antibody is shown in Table 2 and Table 3:
[0082] Table 2. Related information of primary antibody
[0083] Primary Antibody Product Number Manufacturer ALP Antibody sc-271431 Santacruz Osterix Antibodies sc-393325 Santacruz RANKL Antibody sc-377079 Santacruz RUNX2 Antibody 12556S CST OPG antibody sc-390518 Santacruz NFATc1 Antibody A00340-1 Boster TRAF6 Antibody ab137452 abcam MMP9 Antibody 10375-2-AP proteintech c-FOS Antibody 66590-1-Ig proteintech GAPDH Antibody 60004-1-Ig proteintech
[0084] Table 3 Related information of secondary antibodies
[0085] Secondary Antibodies Product Number Manufacturer Mouse secondary antibody (donkey anti-mouse) SA00001-8 proteintech Rabbit secondary antibody (donkey anti-rabbit) SA00001-9 proteintech
[0086] (7) Chemiluminescence imaging: Preheat the chemiluminescence imager, open the imagelab 6.0 software, mix the developer A and B in a 1:1 ratio, place the PVDF membrane in the developing box, evenly add the developer to cover the membrane surface, remove the surface bubbles, close the dark door, set the exposure time in the software, run the instrument for imaging, and analyze the experimental results.
[0087] Western Blot was used to detect the changes in osteogenesis-related proteins among the groups. Figure 5As shown in the figure, compared with the Control (CON) group, the expression of Osterix, RUNX2, and ALP proteins in the Zhenrong Decoction-containing serum group was significantly increased, and the OPG / RANKL ratio was also increased ( Figure 5 Middle E).
[0088] 3. Serum containing Zhenrong Decoction inhibits RANKL-induced osteoclast differentiation
[0089] 3.1 Cultivation of bone marrow mononuclear macrophages
[0090] RAW264.7 cells (RAW264.7 cells were purchased from Wuhan Biological Company, catalog number: CL-0190) were small in size and round in shape. They fell gently to the bottom of the bottle. In the cell culture process, trypsin digestion was not required. The movements were gentle and violent blowing was avoided. The cells were cultured at 1×10 6 The concentration of inoculated in 25cm 2 Add 5 mL of 10% FBSDMEM culture medium into the culture bottle and culture at 37°C for 1 day. Pay attention to observe the color of the culture medium and the growth status of cells every day, and change the medium in time to prevent differentiation.
[0091] 3.2. Determine the concentration of drug-containing serum in each group to intervene in RAW264.7 cells and the results of TRAP staining. RAW264.7 is an osteoclast precursor. The cells are small in size, round or irregular in shape, may have pseudopodia, small and round nuclei, most of which are single-nucleated, and occasionally have 2 to 3 nuclei.
[0092] RAW264.7 cells were induced with 50 ng / mL RANKL on the first day. Figure 6 As shown in A, the cells began to grow larger, with more pseudopodia and larger, oval-shaped nuclei. After 3 days of RANKL induction, Figure 6 As shown in B, cells began to fuse into large cells with more than 3 nuclei; after 5 days of RANKL induction, Figure 6 As shown in middle C, many multinucleated giant cells appeared, with cell sizes ranging from tens to hundreds of microns and irregular shapes. On the 6th day after RANKL induction, Figure 6 As shown in D, multinucleated cells are clearly visible in the center of the cells, the cavities gradually increase, and there are a large number of pseudopodia, up to dozens of cell nuclei. Figure 6 As shown in Figure E, as cells continue to fuse, the cavity in the multinucleated giant cells increases and the border becomes more obvious; TRAP staining was performed on the cells on the 7th day after RANKL induction. Figure 6 As shown in F, the staining is positive, indicating that osteoblasts have been successfully differentiated. The cells are wine red or purple red, with darker staining around the nucleus and under the cell membrane.
[0093] Different concentrations (5%, 10%, 20%) of Zhenrong Decoction-containing serum were added to the RANKL-containing medium to induce RAW264.7 cells. CCK-8 was used to measure cell activity at 24h, 48h, 72h, and 96h of induction. The results are shown in Table 1. Figure 7 As shown. Figure 7 It can be seen that when the concentration of Zhenrong Decoction containing serum is 5% and 10%, the activity of RAW264.7 cells is equivalent to that of cells in the medium containing only RANKL. When the concentration reaches 20%, the activity of RAW264.7 cells is inhibited. Therefore, 5% and 10% concentrations were selected for the experiment.
[0094] 3.3. Serum containing Zhenrong Decoction inhibits gene expression of bone resorption-related markers
[0095] The cells treated with Zhenrong Decoction for 72 h in Section 3.2 were tested by qPCR for the expression of osteoclast resorption-related factors c-fos, NFATc1, CTSK, Trap, Integrinαvβ3, and MMP-9. The results are as follows: Figure 8 As shown, compared with the control group, 5% and 10% Zhenrong Decoction-containing serum can effectively reduce the gene expression levels of c-fos, NFATc1, CTSK, Trap, Integrinαvβ3 and MMP-9, and inhibit bone resorption.
[0096] 3.4. Serum containing Zhenrong Decoction inhibits protein expression of osteoclast bone resorption-related markers
[0097] NFATc1 and c-fos are two transcription factors required for the fusion of osteoclast precursors and their formation through transcriptional regulation of the expression of many osteoclast precursor-related genes.
[0098] The protein expression of related genes TRAF6, MMP-9, c-fos and NFATc1 in cells treated with Zhenrong Decoction for 72 hours in part 3.2 was detected. The results are as follows Fig. 9 As shown in Figure 2, under the induction of RANKL (50 ng / mL), the serum containing Zhenrong Decoction reduced the expression of TRAF6 after 72 hours of intervention, and also reduced the protein expression levels of NFATc1 and c-Fos. The phosphorylation levels of PI3K and AKT in cells treated with Zhenrong Decoction for 72 hours in Section 3.2 were detected. The results are shown in Figure 2. Fig.10 As shown, it was observed that the phosphorylation levels of P-PI3K and P-AKT decreased after the administration of Zhenrong Decoction-containing serum, indicating that Zhenrong Decoction-containing serum may affect the activation of downstream PI3K / AKT and inhibit the differentiation of osteoclasts by inhibiting the activation of RANKL / RANK signaling pathway.
[0099] 4. Effect of Zhenrong Decoction on Ovariectomized Rats
[0100] 4.1. Establishment of PMOP model in female SD rats and animal grouping
[0101] 90 SPF grade SD female rats, three months old, were adapted to feeding (normal diet and water) for 7 days and divided into SHAM (sham operation group) group of 18 rats and OVX (model group) group of 72 rats. The bilateral ovaries were removed in the OVX group, and only the fat around the ovaries was removed in the sham operation group. After the operation, 8UI / rat of penicillin was given for 3 consecutive days for routine anti-infection, and no rats died. Animal groups: sham operation group (SHAM) (normal saline) (1mL / 100g) 18 animals, model group (OVX) (normal saline) (1mL / 100g) 18 animals, positive control group (OVX-EV) (0.1mg / (kg·d)) 18 animals, Zhenrong decoction low-dose group (OVX-ZRDL) (2.2g / (kg·d)) 18 animals, Zhenrong decoction high-dose group (OVX-ZRDH) (4.4g / (kg·d) 18 animals, administration volume 1mL / 100g. After 12 weeks of administration, bone tissue morphology, bone strength and other indicators were observed. The positive control group was given estradiol valerate tablets (EstradiolValerate Tablets, EV) 1mg / tablet, product batch number: 558A.
[0102] 4.2 Observation of bone tissue morphology
[0103] Tibia samples of rats in each group treated for 12 weeks in 4.1 were taken for Masson staining. Fig.11 As shown in Table 4, the relative area ratio of Masson-stained trabeculae in rat tibia was statistically analyzed. Fig.11 As shown in Table 4, at 12 weeks, the trabeculae in the SHAM group were closely arranged, evenly distributed, connected in a reticular manner, with small gaps, and continuous without breaks; 12 weeks after ovarian removal, the OVX group showed a decrease in trabeculae, scattered and irregular distribution, increased trabecular breaks, and increased width between trabeculae; compared with the OVX group, the trabeculae in the OVX-ZRDH group had good morphology and structural integrity, with a large number, small gaps, and few breaks (P < 0.01); the therapeutic effect of the OVX-ZRDL group was slightly worse than that of the OVX-ZRDH group, but compared with the OVX group, the sparse trabeculae were significantly improved (P < 0.05).
[0104] Table 4 Statistical results of relative area ratio of trabecular bone in Masson staining of rat tibia ( n=6)
[0105]
[0106] Note: a: compared with OVX group, *P<0.05, **P<0.01; b: compared with SHAM group, ##P<0.01.
[0107] 4.3. MicroCT scanning to measure rat tibial metaphysis bone mineral density
[0108] The changes in the tibia microstructure in 4.2 were observed by micro-CT three-dimensional reconstruction images and the changes in micro parameters were analyzed, such as Fig.12 , 13 As shown, the tibial trabecular structure was found to be altered in the OVX model group, while OVX-ZRDH and OVX-ZRDL reduced the structural changes caused by OVX.
[0109] Fig.13 The bone mineral density (BMD), bone volume fraction (BV / TV), trabecular number (Tb.N) and trabecular thickness (Tb.Th) were significantly increased.
[0110] 4.4. Results of rat bone strength measurements
[0111] The maximum tibia load of each group was measured, as shown in Table 5 and Fig.15 As shown in the data, 12 weeks after ovariectomy, the maximum tibia load decreased in ovariectomized rats, and there was no significant difference between the SHAM group and the OVX group. The maximum tibia load in the Zhenrong Decoction-treated groups (OVX-ZRDL and OVX-ZRDH) increased significantly compared with the SHAM group and the OVX group.
[0112] Table 5 Maximum tibia load (unit: Kn) (n=6, )
[0113]
[0114] Note: a: compared with OVX group, *P<0.05; b: compared with SHAM group, #P<0.05.
[0115] 4.5. Changes of serum metabolic markers in rats of each group
[0116] Determination of the contents of serum bone metabolism biochemical indicators in each group can reflect the state of bone homeostasis, including bone-specific alkaline phosphatase BALP related to bone formation; tartrate-resistant acid phosphatase TRAP5b, CTK, β-CTX related to bone resorption; IL-6, IL-1β, TNF-α; and estrogen E2.
[0117] The results are shown in Table 6 and Fig.15As shown in the results, after ovariectomy (OVX), the concentration of bone alkaline phosphatase (BALP) decreased significantly (P<0.01), and the concentration of tartrate-resistant acid phosphatase 5b (TRAP5b) increased significantly (P<0.01), indicating that with the decrease of estrogen levels in ovariectomized rats, the inhibition of osteoclast activity was reduced, bone absorption was greater than bone formation, and bone homeostasis was unbalanced. After the administration of Zhenrong Decoction, the content of serum bone phosphatase (P<0.01) was increased, and the content of serum tartrate-resistant acid phosphatase 5b (P<0.01) was reduced, maintaining the balance of bone homeostasis. CTK and β-CTX are related factors for the maturation of osteoclasts. After the administration of Zhenrong Decoction, the levels of CTK and β-CTX decreased (P<0.01). Zhenrong Decoction inhibited osteoclast maturation and reduced bone absorption. In addition, Zhenrong Decoction can reduce the levels of inflammatory factors TNFα, IL-6, and LI-1β in serum.
[0118] Table 6 Effects of Zhenrong Decoction on blood biochemical indexes in ovariectomized rats (n=6, )
[0119] SHAM OVX OVX-EV OVX-ZRDL OVX-ZRDH BALP (ng / mL) 2.50±0.22 <![CDATA[1.60±0.20 ## ]]> 2.30±0.21* 2.0±0.12 2.20±0.13* TRAP5b(U / L) 5.10±0.32 <![CDATA[8.59±0.57 ## ]]> 5.11±0.10** 7.32±0.25* 5.27±0.17** CTK (pg / mL) 2.03±0.32 <![CDATA[3.76±0.15 ## ]]> 2.15±0.20** 3.15±0.11** 2.2±0.13** β-CTX (ng / mL) 12.13±101 <![CDATA[28.59±1.57 ## ]]> 13.15±0.99** 22.29±0.96* 15.37±1.52** TNF-α(pg / mL) 9.57±1.21 <![CDATA[18.46±2.05 ## ]]> 10.98±1.03** 15.05±0.66* 10.47±1.08** IL-6 (pg / mL) 39.9±3.22 <![CDATA[77.80±4.00 ## ]]> 45.65±5.51** 60.87±3.56* 51.14±2.44** IL-1β (pg / mL) 73.23±4.90 <![CDATA[98.80±6.39 ## ]]> 74.98±3.54** 91.72±2.43* 81.14±2.2**
[0120] Note: a: compared with OVX group, *P<0.05, **P<0.01; b: compared with SHAM group, ##P<0.01.
[0121] 4.6. qPCR detection of osteoblast formation-related factors Runx2, RANKL, and OPG in rat femur
[0122] Femoral tissues of rats in each group were taken to detect the gene expression of osteogenesis-related factors, such as Fig.16 As shown in the figure, compared with the SHAM group, the mRNA level of RANKL in the OVX group was significantly increased, and the mRNA expression of OPG and Runx2 was significantly inhibited. After the administration of Zhenrong Decoction, the mRNA expression of Runx2 and OPG increased, which was consistent with the OVE-EV group. It did not affect the expression of RANKL mRNA. This shows that Zhenrong Decoction may upregulate the expression of OPG protein, increase the ratio of OPG / RANKL, and play a role in bone protection.
[0123] 4.7. Western Blot detection of the expression of bone formation-related factors OPG, RANKL, and RUNX2 in rat femur
[0124] Rat femurs were taken to detect the expression of osteogenesis-related proteins, such as Fig.17As shown in the data, compared with the SHAM group, the expression of RANKL protein in the OVX group increased (P < 0.05), and the expression of OPG and RUNX2 proteins decreased (P < 0.01). After 12 weeks of administration of the OVE-EV group and Zhenrong Decoction, the low-dose group began to increase the expression of OPG and RUNX2 proteins (P < 0.05), and the high-dose group increased the expression of OPG protein more significantly (P < 0.01). It did not affect the expression of RANKL protein. This shows that Zhenrong Decoction can increase the ratio of OPG protein / RANKL protein to play a role in bone protection.
[0125] 4.8. qPCR detection of the expression of NFATc1 and c-Fos, factors related to osteoclast formation and differentiation, in rat femur
[0126] In ovariectomized rats, due to the sharp drop in estrogen levels, the inhibition of osteoclast resorption is weakened, and osteoclasts begin to become active. qPCR was used to detect the expression of NFATc1 and c-Fos, factors related to osteoclast formation and differentiation in rat femurs. The results are as follows Fig.18 As shown in the results, the transcription levels of c-fos and NFATc1 in the OVX group were significantly increased (P < 0.01). In the Zhenrong Decoction group and the OVX-EV group, the expression of c-Fos and NFATc1 mRNA was significantly decreased, indicating that Zhenrong Decoction can inhibit the expression of bone resorption-related factors.
[0127] 4.9. Western Blot detection of the expression of TRAF6, c-FOS, and NFATc1 in osteoclast differentiation-related factors in rat femur
[0128] Based on 4.8, changes in RANKL / RANK-related pathway proteins in osteoclast differentiation were observed. Fig.19 As shown in the figure, the decrease in estrogen levels in the OVX group led to active osteoclasts, and the expression of TRAF6, c-fos, and NFATc1 proteins increased, while the OVX-EV group and Zhenrong Decoction intervention significantly decreased, indicating that Zhenrong Decoction can inhibit the expression of bone resorption-related proteins.
[0129] It can be seen from Experimental Example 1 that the Zhenrong Decoction of the present invention can promote the expression of alkaline phosphatase in osteoblasts, increase calcified nodules, increase the gene expression and protein expression levels of osteoblast-related cytokines RUNX2, ALP, and Osterix, and can increase the OPG / RANKL ratio at both molecular and protein levels. After the administration of Zhenrong Decoction, it was found that osteoclast-related transcription factors decreased, inhibited the activation of NFATc1 and c-Fos induced by RANKL, and the phosphorylation level of PI3K / Akt decreased after the intervention of Zhenrong Decoction. Zhenrong Decoction treatment can improve bone loss and bone microstructure disorders in OVX rats, thereby delaying the disease progression of postmenopausal osteoporosis. Further mechanism studies have found that Zhenrong Decoction may upregulate OPG protein expression, increase the OPG / RANKL ratio, play a bone protection role, downregulate the expression of bone resorption-related factors downstream of the RANKL / RANK signaling pathway, participate in regulating bone metabolism balance, and achieve the therapeutic effect of preventing and treating PMOP.
[0130] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing a Chinese medicine granule for treating postmenopausal osteoporosis, characterized in that: The following steps are involved: 30 g of Ligustrum lucidum, 15 g of Morinda officinalis, 15 g of Drynaria fortunei and 10 g of Alisma orientalis were placed in a round-bottom flask, and a 50% ethanol solution with a total mass ratio of 1:10 was added, and reflux extraction was performed at 70-90°C for two times, each time for 1 h. After the extraction, the extract was concentrated at 0.1 MPa and 65°C to a relative density of 1.28 g / mL to obtain the traditional Chinese medicine, and the traditional Chinese medicine was mixed with dextrin in a mass ratio of 1:1 to prepare a soft material, and granules were sieved with a 12-mesh sieve, dried at 0.1 MPa and 50°C for 36 h, and passed through a 10-mesh sieve to obtain the traditional Chinese medicine granules.
2. A Chinese medicine granule obtained by the preparation method according to claim 1.
